Osiris Therapeutics, Inc. (NASDAQ:OSIR) was founded in 1992 and is headquartered in Columbia, Maryland, USA, with 337 full-time employees. It is a company that researches, develops, manufactures, markets and distributes regenerative medicine products in the United States.
Osiris treatment Osiris Therapeutics (OSIR):
Osiris Therapeutics is committed to research, development, production and commercialization of regenerative medicine products, aimed at improving the health and life of patients and reducing overall medical costs. The company has achieved commercial success in orthopedics, sports medicine and wound care, including the Grafix product line, Stravix®, BIO4® and Cartiform®.
Osiris Therapeutics continues to advance research and development by focusing on innovations in regenerative medicine, including the development of bioengineered stem cells and tissue-based products. Company trademarks include: Osiris ® , Grafix ® , GrafixPL ® , GrafixPL PRIME™ Cartiform ® and Prestige Lyotechnologysm. BIO4 ® is a trademark of Howmedica Osteonics Corp., a subsidiary of Stryker Corporation.
Osiris Therapeutics products include Grafix and Stravix, which are used to treat diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers and chronic wounds of severe burns, as well as surgical and traumatic wounds; BIO4 is used for spine, trauma, limbs, Bone repair and regeneration in skull, foot and ankle surgery; and Cartiform for the treatment of articular cartilage lesions in the knee joint and other joints.
Osiris Therapeutics also develops and sells Menvivo for repairing meniscus; and TruSkin for treating chronic wounds.
Osiris Therapeutics sells and distributes its products directly to doctors, hospitals and other medical service providers, as well as agents and distributors.